Dose-dependent effect of daptomycin on the artificial prolongation of prothrombin time in coagulation abnormalities: in vitro verification

Table 2 Baseline PT-INR values and ratios of PT-INR to the baseline PT- INR at designated daptomycin concentrations

Reagent	Plasma group	Baseline PT-INR (mean ± SD)	PT-INR₅₀/PT-INR₀ ^a	PT-INR₁₀₀/PT-INR₀ ^a	PT-INR₁₅₀/PT-INR₀ ^a
1: HemosIL RecombiPlasTin 2G	A (INR 1)	0.96 ± 0.00	1.01	1.03	1.04
	B (warfarin, INR 2)	1.70 ± 0.01	1.04	1.09	1.14
	C (warfarin, INR 3)	2.57 ± 0.01	1.07	1.11	1.17
	D (LC, INR 2)	1.63 ± 0.02	1.02	1.07	1.11
2: Neoplastin Plus	A (INR 1)	0.97 ± 0.02	1.03	1.05	1.09
	B (warfarin, INR 2)	1.82 ± 0.01	1.03	1.05	1.06
	C (warfarin, INR 3)	2.75 ± 0.02	1.06	1.07	1.11
	D (LC, INR 2)	1.83 ± 0.00	1.02	1.07	1.11
3: STA Neoplastin R	A (INR 1)	0.99 ± 0.02	1.03	1.09	1.09
	B (warfarin, INR 2)	1.88 ± 0.02	1.09	1.12	1.19
	C (warfarin, INR 3)	2.86 ± 0.02	1.09	1.13	1.18
	D (LC, INR 2)	1.54 ± 0.01	1.07	1.14	1.22

PT prothrombin time, INR international normalized ratio, SD standard deviation, LC liver cirrhosis
^a PT-INR₀ represents the baseline PT-INR. PT-INR₅₀, PT-INR₁₀₀, and PT-INR₁₅₀ represent the PT-INR at daptomycin concentrations of 50, 100, and 150 μg/mL, respectively. The relative change in PT-INR was calculated using the mean values of PT-INR measured in triplicate at each daptomycin concentration

ISSN: 2050-6511